Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02215395
Recruitment Status : Completed
First Posted : August 13, 2014
Last Update Posted : August 15, 2017
Sponsor:
Information provided by (Responsible Party):
Population Council

Brief Summary:
To evaluate the pharmacokinetics (PK) of EE and NES released from the CVR in the presence of a single dose and multiple doses of antimycotic co-medication (miconazole nitrate suppository or cream).

Condition or disease Intervention/treatment Phase
Antifungal Drug Adverse Reaction Drug: NES/EE CVR Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication (Miconazole Nitrate) on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring Releasing a Daily Dose of 150 ug of NES and 15 ug of EE
Study Start Date : March 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015


Arm Intervention/treatment
Experimental: CVR treatment cycle
Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
Drug: NES/EE CVR
Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Other Name: Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)




Primary Outcome Measures :
  1. Drug Drug Interaction of NES/EE CVR and topical anti-fungal medication [ Time Frame: Week 12 ]
    To evaluate adverse reactions to a topical anti-fungal medication when used in conjunction with the NES/EE CVR



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy women, inclusive of ages 18-35* years at the enrollment visit
  • Intact uterus and both ovaries
  • Prior history of regular menstrual cycles that usually occur every 28 ± 7 days when not using hormonal contraception; if postpartum or post-abortal, history of regular menstrual cycles of 21-35 days in length and resumption of at least one cycle with a cycle length consistent with her past cycles
  • In the opinion of the investigator, able to comply with the protocol, e.g. live within the study site catchment area or within a reasonable distance from the study site
  • May be sterilized or at risk of becoming pregnant
  • Willing to use a non-hormonal method of contraception for one month prior to the initial insertion of the NES/EE CVR and the one month washout period
  • Willing to abstain from sexual intercourse during the miconazole nitrate treatment period(s)
  • Signed informed consent prior to entry into the trial

Exclusion Criteria:

  • Known hypersensitivity to estrogens or progestins
  • Pregnant, trying to become pregnant, or breastfeeding
  • Known hypersensitivity to silicone rubber
  • Undiagnosed abnormal vaginal bleeding
  • Undiagnosed vaginal discharge, vaginal lesions or abnormalities. Subjects diagnosed at screening with a Chlamydia or gonococcus infection may be included in the trial following treatment; partner treatment is also recommended. Investigators should make a determination if subjects are at high risk for reinfection, e.g., multiple sex partners, untreated partner, and whether such subjects can be included
  • History of pelvic inflammatory disease since the subject's last pregnancy
  • History of toxic shock syndrome
  • In accordance with the Bethesda system of classification: Women with a current (within the last 20 months) abnormal Pap smear suggestive of high-grade pre-cancerous lesion (s), including HGSIL
  • Cystoceles or rectoceles or other anatomical abnormality that would preclude use of a vaginal ring
  • Women planning to undergo major surgery during the trial
  • Women who smoke 15 cigarettes or more per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for cardiovascular disease and thromboembolism, e.g., lipid levels, glucose level, BP, BMI, family history of cardiovascular disease at a young age
  • Current or past thrombophlebitis or thromboembolic disorders
  • History of venous thrombosis or embolism in a first-degree relative, <55 years of age suggesting a familial defect in the blood coagulation system, which in the opinion of the PI, suggests that use of a hormonal contraceptive could pose a significant risk
  • Cerebrovascular or cardiovascular disease
  • History of retinal vascular lesions, unexplained partial or complete loss of vision
  • Known or suspected carcinoma of the breast
  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
  • Past history of any other carcinoma unless in remission for more than five years
  • Current or history of medically diagnosed severe depression, which, in the opinion of the investigator, could be exacerbated by the use of a hormonal contraceptive
  • Headaches with focal neurological symptoms
  • Severe constipation in the opinion of the investigator
  • History of cholestatic jaundice of pregnancy or jaundice with prior steroid use
  • Benign or malignant liver tumors; active liver disease
  • Diastolic blood pressure (BP) >85 mm Hg and/or systolic BP >135 mm Hg after 5-10 minutes rest (at screening)
  • Known or suspected alcoholism or drug abuse within their lifetime
  • Elevated serum fasting clinical chemistry values or complete blood count (CBC) values designated clinically significant by the investigator and/or medically qualified sub-investigator
  • Screening hemoglobin levels less than 12.5 g/dL or hematocrit less than 38%.
  • Participation in another clinical trial involving an investigational drug within the last 30 days (prior to screening)
  • BMI >29
  • Use of liver enzyme inducers on a regular basis
  • Use of monthly injectable contraceptives, unless suspended 2 months before initiation of the treatment. Use of Depo-Provera [depo-medroxyprogesterone (DMPA)] unless suspended 6 months before treatment
  • Current use of implanted hormonal contraceptives, including Mirena [progestin containing intrauterine system (IUS)], Jadelle, Norplant, Implanon or Nexplanon (if now available in the USA).**
  • Known HIV, Hepatitis B or Hepatitis C infection
  • History of frequent vaginal infections in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02215395


Locations
Layout table for location information
United States, Missouri
QPS Bio-Kinetic
Springfield, Missouri, United States, 65802
Sponsors and Collaborators
Population Council
Investigators
Layout table for investigator information
Principal Investigator: Dennis Morrison, MD QPS-Biokinetic

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Population Council
ClinicalTrials.gov Identifier: NCT02215395    
Other Study ID Numbers: 571
First Posted: August 13, 2014    Key Record Dates
Last Update Posted: August 15, 2017
Last Verified: August 2017
Keywords provided by Population Council:
Nestorone
miconazole nitrate
Additional relevant MeSH terms:
Layout table for MeSH terms
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Miconazole
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Contraceptive Agents
ST 1435
Estradiol
Polyestradiol phosphate
Ethinyl Estradiol
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptive Agents, Female
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP3A Inhibitors